Mangoceuticals, INC 8-K filings

Mangoceuticals has been granted a 180-day extension to meet Nasdaq's minimum bid price requirement and has received conditional approval for compliance with the minimum stockholders' equity requirement.

Mangoceuticals, Inc. has acquired a global patent portfolio for an oral solution aimed at preventing infections, marking its entry into the non-prescription nutraceutical market.

Mangoceuticals, Inc. has entered into agreements to sell preferred stock and warrants for $1.65 million and secured a $25 million equity line of credit.

Mangoceuticals, Inc. stockholders approved amendments to the 2022 Equity Incentive Plan and a reverse stock split at a special meeting on March 25, 2024.

Mangoceuticals has been granted an extension by Nasdaq until April 29, 2024, to regain compliance with the minimum stockholders' equity requirement for continued listing.

Mangoceuticals issued a warrant to Boustead Securities for 42,000 shares at $0.375 per share following the full exercise of an over-allotment option in their recent public offering.